These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32939319)

  • 1. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients.
    Lum LG; Thakur A; Choi M; Deol A; Kondadasula V; Schalk D; Fields K; Dufrense M; Philip P; Dyson G; Aon HD; Shields AF
    Oncoimmunology; 2020 Jun; 9(1):1773201. PubMed ID: 32939319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide.
    Fadul CE; Thakur A; Kim J; Kassay-McAllister J; Schalk D; Lopes MB; Donahue J; Purow B; Dillon P; Le T; Schiff D; Liu Q; Lum LG
    J Neurooncol; 2024 Jan; 166(2):321-330. PubMed ID: 38263486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.
    Lum LG; Al-Kadhimi Z; Deol A; Kondadasula V; Schalk D; Tomashewski E; Steele P; Fields K; Giroux M; Liu Q; Flaherty L; Simon M; Thakur A
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness.
    Thakur A; Ung J; Tomaszewski EN; Schienschang A; LaBrie TM; Schalk DL; Lum LG
    Oncoimmunology; 2021 Jun; 10(1):1930883. PubMed ID: 34123574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
    Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
    Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
    Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells.
    Yankelevich M; Thakur A; Modak S; Chu R; Taub J; Martin A; Schalk DL; Schienshang A; Whitaker S; Rea K; Lee DW; Liu Q; Shields A; Cheung NK; Lum LG
    Res Sq; 2023 Nov; ():. PubMed ID: 37986911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial.
    Lum LG; Thakur A; Al-Kadhimi Z; Colvin GA; Cummings FJ; Legare RD; Dizon DS; Kouttab N; Maizel A; Colaiace W; Liu Q; Rathore R
    Clin Cancer Res; 2015 May; 21(10):2305-14. PubMed ID: 25688159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.
    Thakur A; Scholler J; Schalk DL; June CH; Lum LG
    J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune T cells can transfer and boost anti-breast cancer immunity.
    Thakur A; Rathore R; Kondadasula SV; Uberti JP; Ratanatharathorn V; Lum LG
    Oncoimmunology; 2018; 7(12):e1500672. PubMed ID: 30524893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.
    Lum LG; Thakur A; Liu Q; Deol A; Al-Kadhimi Z; Ayash L; Abidi MH; Pray C; Tomaszewski EN; Steele PA; Schalk DL; Yano H; Mitchell A; Dufresne M; Uberti JP; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):925-33. PubMed ID: 23529012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.
    Vaishampayan UN; Thakur A; Chen W; Deol A; Patel M; Dobson K; Dickow B; Schalk D; Schienschang A; Whitaker S; Polend A; Fontana JA; Heath EI; Lum LG
    Clin Cancer Res; 2023 Jan; 29(1):122-133. PubMed ID: 36255393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1
    Lum LG; Thakur A; Elhakiem A; Alameer L; Dinning E; Huang M
    Front Oncol; 2020; 10():544. PubMed ID: 32432032
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.
    Zitron IM; Thakur A; Norkina O; Barger GR; Lum LG; Mittal S
    BMC Cancer; 2013 Feb; 13():83. PubMed ID: 23433400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer.
    Qiao G; Kone LB; Phillips EH; Lee SS; Brown GE; Khetani SR; Thakur A; Lum LG; Prabhakar BS; Maker AV
    Oncogene; 2022 Apr; 41(14):2054-2068. PubMed ID: 35177811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study.
    Lum LG; Thakur A; Pray C; Kouttab N; Abedi M; Deol A; Colaiace WM; Rathore R
    Bone Marrow Transplant; 2014 Jan; 49(1):73-9. PubMed ID: 24056738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.
    Luangwattananun P; Sangsuwannukul T; Supimon K; Thuwajit C; Chieochansin T; Sa-Nguanraksa D; Samarnthai N; O-Charoenrat P; Junking M; Yenchitsomanus PT
    Int Immunopharmacol; 2023 Nov; 124(Pt B):111012. PubMed ID: 37804657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells.
    Yano H; Thakur A; Tomaszewski EN; Choi M; Deol A; Lum LG
    J Transl Med; 2014 Jul; 12():191. PubMed ID: 25008236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
    Yankelevich M; Thakur A; Modak S; Chu R; Taub J; Martin A; Schalk D; Schienshang A; Whitaker S; Rea K; Lee DW; Liu Q; Shields AF; Cheung NV; Lum LG
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial.
    Lum LG; LeFever AV; Treisman JS; Garlie NK; Hanson JP
    J Immunother; 2001; 24(5):408-19. PubMed ID: 11696696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.